RESEARCH MONOGRAPH · KDC-MN-379

Lisdexamfetamine

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

76/100

Clever prodrug design that smoothed amphetamine PK and reduced abuse liability without losing efficacy

Lisdexamfetamine is one of the better executed prodrug designs in psychiatric pharmacology. Take d-amphetamine, conjugate it to L-lysine through an amide bond, and you've got a molecule that has no CNS activity on its own. Red blood cell peptidases cleave the lysine off, releasing d-amphetamine into circulation. The cleavage is rate-limited and saturable, so peak plasma amphetamine is lower and AUC is flatter than equivalent IR d-amphetamine.

What this buys you: a smoother dose-response curve, fewer plasma spikes, longer effective duration (10 to 12 hours in most patients), and crucially, much harder to abuse intranasally or intravenously because the cleavage requires enzymatic conversion in blood. You can't bypass it by snorting or injecting the prodrug. That's a real pharmacological abuse-deterrent, not the marketing kind.

The phase 3 program for ADHD was extensive. Biederman and the Shire team ran enough head-to-head and registration studies to make Vyvanse a top three ADHD drug worldwide. Effect sizes match or modestly exceed Adderall XR with cleaner PK. The binge eating disorder approval (2015) is the more interesting off-the-beaten-path indication; the mechanism story there is genuinely unclear, probably reward-circuit modulation more than simple appetite suppression.

What we like for research use: the cleanest way to study chronic d-amphetamine exposure without the peak-trough dynamics that confound mechanism work. The prodrug acts as its own slow-release vehicle.

What we don't like: cost, lisdexamfetamine was Shire's blockbuster for years and reference-standard material is still pricey relative to plain d-amphetamine. Generic versions have helped but it's not a cheap research chemical.

Sourcing reality: same Schedule II constraints as amphetamine, plus the prodrug itself is a controlled substance in its own right. HPLC analysis is straightforward, the lysine conjugate gives a clean signal, and stability in solid form is good for years if stored dry.

The staying power is high because the abuse-deterrent prodrug logic is so clean that it'll get applied to other amphetamines and stimulants going forward. Serdexmethylphenidate is the methylphenidate analog already on market.

Evidence: 90
Mechanism: 88
Reliability: 88
Safety: 70
Sourcing: 55
Value: 55
Signal: 80
Staying power: 80

Plain-language summary Intrigue 70 / 100

Lisdexamfetamine is a clever prodrug of d-amphetamine, sold as Vyvanse since 2007. The trick is that the amphetamine molecule is chemically tied to the amino acid lysine, which makes the conjugate biologically inactive. Once swallowed, enzymes inside red blood cells slowly cleave the lysine off, releasing free d-amphetamine over several hours. The result is a smoother, flatter blood curve than immediate-release amphetamine and a lower abuse ceiling, since crushing or injecting it does not speed up the enzymatic conversion. Approved for ADHD and binge eating disorder. Schedule II despite the abuse-deterrent design. The standard reference for prodrug-style stimulant engineering. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Prodrug d-amphetamine (lysine conjugate)

L-lysine-d-amphetamine conjugate; a prodrug providing slow conversion to active d-amphetamine, with reduced abuse potential.

Abstract

Lisdexamfetamine ((2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide; CAS 608137-32-2; molecular formula C15H25N3O; molecular weight 263.38) is a prodrug of d-amphetamine in which the amphetamine amino group is conjugated with L-lysine via a peptide bond. Approved by the FDA in 2007 (Vyvanse). Mechanism: the prodrug is biologically inactive; following oral absorption, red blood cell cytosolic enzymes hydrolyze the lysine-amphetamine bond, releasing free d-amphetamine over several hours. The slow, sustained release produces a flatter plasma curve than IR amphetamine and reduces the rate of dopamine increase that drives abuse liability. The lysine conjugation also means parenteral routes (IV, snorted) do not produce a faster onset, since the cleavage requires enzymatic activity. Approved indications: ADHD and binge eating disorder. Plasma half-life of the released d-amphetamine is approximately 11 hours. Schedule II. Used as the canonical abuse-deterrent stimulant prodrug.

Mechanism of action

Inactive prodrug; red blood cell enzymes cleave lysine to release d-amphetamine slowly. Reduced abuse liability via slowed pharmacokinetics.

Reported research dose ranges

Clinical 30 to 70 mg in the published literature.

References

Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat 2010.
Biederman J, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD. Clin Ther 2007.
McElroy SL, et al. Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder. JAMA Psychiatry 2015.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-379

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Lisdexamfetamine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs